2nd Circ. Tosses Securities Suit Over Bextra, Celebrex
Former Pfizer Inc. executives have fended off a challenge by shareholders to revive a derivative action over the pharmaceutical makers' marketing of anti-inflammatory drugs Bextra and Celebrex, with an appeals court...To view the full article, register now.
Already a subscriber? Click here to view full article